Assessment of the Efficacy of the Artificial Pancreas Combined With a Qualitative Meal Size Estimation to Control Postprandial Glucose Levels
NCT04031599 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2022-01-28
Summary
Postprandial glycemic excursions are major determinants of overall glycemic control in type 1 diabetes. Carbohydrate content of ingested meals is the main determinant of post-meal glucose excursion. Accurate carbohydrate counting is a critical aspect of managing postprandial blood glucose levels. accurate carbohydrate counting is considered by patients as a significant burden and frustrating task.
The closed-loop system (CLS) is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings.
The objective of this study is to compare the efficacy of two strategies to regulate glucose levels in outpatient settings in adults with type 1 diabetes: 1) single-hormone CLS with rapid acting insulin analogue combined with carbohydrate counting; 2) single-hormone CLS with rapid acting insulin analogue combined with simplified qualitative meal-size estimation.
A sub-study will also be proposed to participants. Postprandial exercise combines two situations complicating CLS operation: a high plasma insulin due to insulin on-board related to meal boluses and rapid blood glucose changes (postprandial blood glucose excursion and then drop during exercise) making input from the glucose sensor less accurate. The objective of this sub-study will be to explore the safety and efficacy of the CLS using the combined strategy of pre-meal exercise announcement and meal bolus reduction of 33% when exercise is performed 1 hour compared to 2 hours post meal time.
Conditions
Interventions
- DEVICE
-
Single-hormone closed-loop system
Every 10 minutes, the glucose levels as measured by the sensor will be transferred automatically to a LG Google Nexus Smartphone that the algorithm is running on, which will calculate the recommended doses and will send them wirelessly to the infusion pump.
- DEVICE
-
Insulin pump
Tandem Diabetes Care
- DEVICE
-
Continuous glucose monitoring system
Dexcom G6
- DRUG
-
Aspart or Lispro
Aspart or lispro will be infused with the infusion pump
- OTHER
-
Carbohydrate counting
Participants will be required to enter an estimate of the carbohydrate content of their meal into the phone. Insulin boluses will be calculated based on grams of carbohydrates and participant's insulin-to-carbohydrate ratio. Carbohydrate-matching full prandial bolus will be given 5 to 10 minutes before the meal.
- OTHER
-
Simplified qualitative meal-size estimation strategy
A pre-meal partial prandial bolus will be given 5-10 minutes before the meal. The partial bolus will be based on the estimated meal size (small, regular, large and extra-large). The closed-loop system will give the remaining insulin needed based on the sensor readings. For this strategy, meal size will be defined as: small as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, extra-large meal for anything above 90g CHO.
- OTHER
-
3-week intervention
Glucose levels will be regulated by the single-hormone closed-loop system for 3 consecutive weeks.
- OTHER
-
1-hour postprandial exercise (sub-study)
60 minute exercise will be started one hour after the meal time.
- OTHER
-
2-hour postprandial exercise (sub-study)
60 minute exercise will be started two hours after meal time
- OTHER
-
Exercise announcement and meal bolus reduction (sub-study)
Meal bolus reduction of 33% at meal time and exercise announcement (increased target glucose from 6 to 9mmolL) to the CLS algorithm
Sponsors & Collaborators
-
Institut de Recherches Cliniques de Montreal
lead OTHER
Principal Investigators
-
Rémi Rabasa-Lhoret · Montreal Clinical Research Institute
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-07-10
- Primary Completion
- 2021-11-27
- Completion
- 2021-12-14
Countries
- Canada
Study Locations
More Related Trials
-
Closed-loop Control of Glucose Levels (Artificial Pancreas) for 12 Days in Adults With Type 1 Diabetes
NCT02846831 ·Status: COMPLETED ·Phase: PHASE2
-
Closed-loop Control of Postprandial Glucose Levels in Adults With Type 1 Diabetes
NCT02416765 ·Status: COMPLETED ·Phase: PHASE2
-
Closed-loop Control of Glucose Levels (Artificial Pancreas) for 5 Days in Adults With Type 1 Diabetes
NCT02488616 ·Status: WITHDRAWN ·Phase: PHASE2
-
Dual-hormone Artificial Pancreas Versus Single-hormone Under Exercise and a Meal Challenge
NCT06082973 ·Status: COMPLETED ·Phase: NA
-
Closed-loop Control of Glucose Levels (Artificial Pancreas) During Exercise in Adults With Type 1 Diabetes
NCT01930110 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Artificial Pancreas With and Without a Meal Detection Module on Glycemic Control in Adolescents With Type 1 Diabetes After a Missed Bolus
NCT02909829 ·Status: COMPLETED ·Phase: NA
-
Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide
NCT06387199 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes
NCT02855307 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial to Compare Automated Lyumjev Delivery With Carbohydrate Counting, Qualitative Meal-size Estimation, and Meal Detection in Type 1 Diabetes
NCT06021158 ·Status: RECRUITING ·Phase: PHASE2
-
Closed-loop Control of Overnight Glucose Levels (Artificial Pancreas) in Type 1 Diabètes Adults With Hypoglycemia Unawareness and Documented Nocturnal Hypoglycemia
NCT02282254 ·Status: COMPLETED ·Phase: PHASE2
-
Closed-loop Control of Glucose Levels After Meal Intake in Adults With Type 1 Diabetes
NCT01930097 ·Status: COMPLETED ·Phase: PHASE2
-
Closed-loop Control of Glucose Levels (Artificial Pancreas) for 15 Weeks in Adolescents and Adults With Type 1 Diabetes
NCT02846857 ·Status: WITHDRAWN ·Phase: PHASE2
-
Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation - Part 2
NCT02798250 ·Status: COMPLETED ·Phase: PHASE2
-
Closed-loop Control of Postprandial Glucose Levels After Meals With Different Macronutrients Content in Adults With Type 1 Diabetes
NCT02774876 ·Status: COMPLETED ·Phase: PHASE2
-
Closed-loop Control of Glucose Levels (Artificial Pancreas) for 60 Hours in Adults With Type 1 Diabetes
NCT01966393 ·Status: COMPLETED ·Phase: PHASE2
-
Closed-loop Control of Overnight Glucose Levels in Adults and Adolescents With Type 1 Diabetes
NCT01905020 ·Status: COMPLETED ·Phase: PHASE2
-
Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus
NCT02514954 ·Status: COMPLETED ·Phase: PHASE1
-
Using Simplified Meal Boluses Versus Carbohydrate Counting in Adolescents With Hybrid Closed Loop Systems
NCT06575790 ·Status: RECRUITING ·Phase: NA
-
Simple Meal Management Using Automated Insulin Delivery System
NCT06130215 ·Status: RECRUITING ·Phase: NA
-
Artificial Pancreas With Different Stress Assessments in the Outpatient Setting
NCT04142229 ·Status: COMPLETED ·Phase: NA
-
Closed-loop Control of Glucose Levels (Artificial Pancreas) for 24 Hours in Adults and Adolescents With Type 1 Diabetes
NCT01754337 ·Status: COMPLETED ·Phase: PHASE2
-
The Steno Opti-Bolus-Timing Studies
NCT07021690 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Insulin-plus-pramlintide Closed-loop Strategy to Regulate Glucose Levels Without Carbohydrate Counting
NCT03800875 ·Status: COMPLETED ·Phase: PHASE2
-
Exercise-Induced Hypoglycemia Prevention in Adults With Type 1 Diabetes Using an Artificial Pancreas
NCT03859401 ·Status: COMPLETED ·Phase: NA
-
Mixed Meal Test in Type 1 Diabetes on Insulin Pump Therapy: Optimization of Artificial Pancreas
NCT02003274 ·Status: UNKNOWN ·Phase: NA